HOUSTON, May 15, 2026
Moleculin Biotech reported first quarter 2026 financial results while advancing its pivotal MIRACLE Phase 2B/3 trial evaluating Annamycin in combination with cytarabine (AnnAraC) for patients with relapsed or refractory acute myeloid leukemia (AML). The company confirmed that enrollment surpassed the first interim analysis threshold, with early blinded data continuing to show a promising 40% composite complete remission (CRc) rate across a difficult-to-treat AML population. Management stated that the first interim unblinding is expected in June 2026 following the enrollment of the first 45 patients, marking what executives described as a potentially transformative period for the company and its lead oncology program.
Moleculin believes Annamycin, also known as naxtarubicin, could potentially redefine the anthracycline chemotherapy class by overcoming two major limitations of conventional therapies: multidrug resistance and cardiotoxicity. Traditional anthracyclines remain a foundational treatment in leukemia but are often associated with cumulative heart damage that restricts long-term dosing. According to the company, Annamycin was specifically designed to avoid these cardiotoxic effects while maintaining strong anti-cancer activity. Earlier clinical studies and current MIRACLE trial observations continue to support the therapy’s potential role in improving outcomes for relapsed AML patients who have limited treatment options and poor survival prospects.
MIRACLE Trial Enrollment Accelerates Across Global Sites
The adaptive-design MIRACLE trial continues expanding across clinical sites in the United States and Europe, with Moleculin expecting enrollment of the 90th patient during the third quarter of 2026. Following this milestone, the company plans another interim unblinding analysis before initiating Part B of the study in the second half of 2026. The trial is evaluating AnnAraC in adults with relapsed or refractory AML, a highly aggressive blood cancer where current salvage therapies often fail to deliver durable remissions. Moleculin reported that blinded efficacy trends remain consistent between the 30-patient and 45-patient enrollment marks, maintaining the previously disclosed 40% CRc rate, which management believes strengthens confidence in the program’s clinical potential.
The company also outlined a broader long-term development roadmap for Annamycin, including plans to initiate recruitment for third-line AML patients and pediatric AML studies in 2027. Moleculin further anticipates primary efficacy data for second-line AML subjects in 2028, alongside a potential rolling New Drug Application (NDA) submission for accelerated approval based on remission endpoints from the MIRACLE study. Beyond AML, Moleculin plans to begin a pancreatic cancer clinical study with Atlantic Health during the second half of 2026, further expanding the therapeutic reach of its oncology pipeline.
Financial Position Supports Near-Term Development Goals
Advertisement
For the first quarter ended March 31, 2026, Moleculin reported research and development expenses of $5.4 million, compared with $3.4 million during the same period in 2025. The increase was primarily driven by expanding MIRACLE clinical trial operations in Europe, additional nonclinical development work, and broader research activities supporting the Annamycin program. General and administrative expenses remained stable at approximately $2.5 million year-over-year. The company ended the quarter with approximately $10.3 million in cash and cash equivalents, supported by financing transactions completed during the quarter that generated roughly $8.3 million in gross proceeds.
In addition to Annamycin, Moleculin continues advancing other pipeline programs, including WP1066, an immune and transcription modulator targeting brain tumors and pancreatic cancer, along with WP1122, an antimetabolite candidate being explored for viral diseases and cancer indications. However, the MIRACLE trial remains the company’s primary strategic focus as investors and clinicians await the first unblinded efficacy data expected in the coming weeks. If the remission trends hold following unblinding, Moleculin could emerge as a significant player in the competitive AML treatment landscape, particularly for patients requiring safer anthracycline-based therapies.
Source: Moleculin Biotech press release
